Fresh analysis reveals that patients who stop using popular weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end traditional diet and exercise plans.
Published data in a leading medical journal shows that while obese individuals frequently drop about a fifth of their body weight while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"People buying such treatments must be cognizant of the risk of rapid rebound weight gain when the treatment concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to original mass in about 18 months.
Comparing Approaches
The analysis, which reviewed 37 of studies involving thousands of patients, contrasted the results of GLP-1 agonists with other pills.
Scientists note that individuals who shed pounds through lifestyle changes alone usually see a slower creep back—approximately 0.1 kg a month—post-intervention.
The Reason for the Rapid Rebound
Nutrition scientists suggest the way of the injections explains the accelerated regain.
These medications copy a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 levels far above than normal could lead to the body to produce less of its own natural hormone, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication means appetite is no longer kept in check, making binge eating much more probable."
An Ongoing Issue?
Medical guidelines suggest the jabs for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Professionals contend that, given the likelihood of weight regain, the treatment should be considered life-long.
This opinion is echoed by pharmaceutical companies, who say that the findings "emphasize the chronic nature of obesity," akin to managing conditions like hypertension.
Patient Testimonies
Users who have come off the jabs describe a sudden resurgence of appetite.
"It was like something that goes on and I was suddenly ravenous," described one woman.
The struggle is compounded if individuals have not adopted sustainable dietary or behavioural changes during therapy.
Widespread Use
Figures suggest that millions of adults in the UK have used these injections in the past year, with demand continuing to grow.
- Use is greater among females compared to men.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
Ultimately, clinicians caution that while the jabs are powerful tools for weight loss, they are not a standalone cure and long-term success relies on combined behavioural changes.
